Search EXEL
EXELIXIS, INC.
Nasdaq · CIK 939767
Last close58.39
Daily change+0.45 (0.78%)
10 Years gain+359.04%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
EXEL · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 0101
Fundamental
70.1Momentum
100.0Acceleration
100.0Confidence
85.0Annual Revenue20
Quarterly Revenue85
Annual CFO20
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth16.9 / 25
Quality18.3 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.2263 percentage points.
Operating leverageOperating margin improved by 10.3654 percentage points.
Share count reductionDiluted share count declined 9.8904%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM11.5%OK
Revenue CAGR 3Y12.93%OK
Gross Margin96.73%OK
Operating Margin39.49%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC71.33%OK
Incremental Operating Margin 3Y61.38%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-9.89%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Jan 02, 2026 | $2.32B | $2.24B | $872.19M | $884.27M | $875.84M | 96.39% | 37.59% | 37.75% | 61.65% | 281.86M |
| 2025 FY Jan 03, 2025 | $2.17B | $2.09B | $604.62M | $699.97M | $671.54M | 96.49% | 27.88% | 30.96% | 39.78% | 296.13M |
| 2025 FY Dec 29, 2023 | $1.83B | $1.76B | $170.89M | $333.32M | $292.86M | 96.04% | 9.34% | 16% | 11.03% | 321.46M |
| 2024 FY Dec 30, 2022 | $1.61B | $1.55B | $201.48M | $362.61M | $334.91M | 96.41% | 12.51% | 20.79% | 16.55% | 324.56M |
| 2023 FY Dec 31, 2021 | $1.43B | $1.38B | $286.67M | $400.80M | $346.58M | 96.32% | 19.98% | 24.15% | 31.98% | 322.36M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.41B | sum latest 4 fiscal quarters Revenue | OK | 0000939767-26-000098, 0000939767-25-000128 |
| Revenue Growth TTM | 11.5% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000939767-26-000098, 0000939767-25-000128 |
| Revenue CAGR 3Y | 12.93% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000939767-26-000021 |
| Revenue CAGR 5Y | 18.63% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000939767-26-000021 |
| Gross Profit CAGR 3Y | 12.92% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000939767-26-000021 |
| Operating Income Growth | 51.19% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000939767-26-000098, 0000939767-25-000128 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 96.73% | Gross Profit / Revenue | OK | 0000939767-26-000098, 0000939767-25-000128 |
| Operating Margin | 39.49% | Operating Income / Revenue | OK | 0000939767-26-000098, 0000939767-25-000128 |
| ROIC | 71.33% | NOPAT / Average Invested Capital | OK | 0000939767-26-000098, 0000939767-25-000128 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000939767-26-000098 |
| Current Ratio | 3.46x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $9.26 | Revenue / Diluted Shares | OK | 0000939767-26-000098, 0000939767-25-000128 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |